九典制药：获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, JIZM01 and JIZM02, targeting specific medical conditions [1] Group 1: Drug Information - JIZM01 is intended for the treatment of closed soft tissue contusions and joint sprains [1] - JIZM02 is designed for shoulder periarthritis [1] Group 2: Regulatory Approval - The approval was granted in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations [1] - The company will commence clinical trial research after completing the necessary preparatory work [1]